OneOncology

The Enhancing Oncology Model (EOM) attracted more than 2800 practitioners across 561 sites of care; a group of practices in the American Oncology Network enrolled under a single tax ID number.

While the final number of EOM practices will be fewer than the numbers in the OCM, the presence of Tennessee Oncology, Texas Oncology, and Northwest Medical Specialties will ensure participation of key leaders who succeeded in the OCM and have weighed in on what's needed in its replacement.

Initiating targeted therapy for eligible patients with advanced non–small cell lung cancer (NSCLC) was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner.

A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.

The session, “Payment Reform: Lessons Learned from the Oncology Care Model (OCM) and Implications for the Enhancing Oncology Model (EOM)," comes less than a month before the EOM is set to begin.

Thomas Stricker, MD, PhD, and Gregory Vidal, MD, PhD, are both first authors on their respective abstracts involving patients with advanced non-small cell lung cancer in the community setting.

The multisite practice receives a key designation from a major and announces it is formally taking over a proton therapy center where its radiation oncologists already serve patients.

Stephen M. Schleicher, MD, MBA, Tennessee Oncology, co-authored a recent paper on the complexities of the rural cancer experience; the principal conclusion was potential for a streamlined care process to optimize care efficiencies and access, thereby improving patient outcomes.

OneOncology now has partner practices in 14 states.

Under the transaction, TPG, an asset management firm, will acquire a majority interest in OneOncology and AmerisourceBergen will have a minority interest; OneOncology physician leaders and practices will retain minority interests as well.

Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.

The practice is OneOncology's 16th partners overall and its first in Florida.

Oncologists express concerns about the replacement for the Oncology Care Model; the EOM is set to start July 1, 2023.

Coming soon: the inaugural episode of "Oncology Onward: Conversations With Innovators and Changemakers in Cancer Care,” with hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA.

Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.

Davey B. Daniel, MD, chief medical officer at OneOncology, shares his insights on health equity practices, as well as the importance of developing clinical models within community oncology.

Stephen M. Schleicher, MD, MBA, chief medical officer at Tennessee Oncology, discusses the present state of value-based oncology care and what the future may bring when the Enhancing Oncology Model kicks off on July 1.

A panel of experts discussed the explosion of information and advances in cancer genomics and the accompanying challenges of understanding the data and taking action.

Richard L. Martin III, MD, MPH, medical director for Health Equity and Community Engagement, Tennessee Oncology; president, Tennessee Oncology Practice Society.

In abstracts presented at the 64th American Society of Hematology Annual Meeting and Exposition, the investigational BTK inhibitor pirtobrutinib showed promising efficacy and safety in several types of B-cell lymphoma.

Constructive advice on improving the Enhancing Oncology Model (EOM) from our expert panel.

The Enhancing Oncology Model allows pooling of groups of practices for quality measurement, which was not permitted under the OCM.